<DOC>
	<DOC>NCT01045954</DOC>
	<brief_summary>This study will be conducted in subjects with Type 1 diabetes mellitus on multiple daily insulin injections to determine the correct insulin dosing formulas. Subjects will be evaluated using continuous glucose monitoring.</brief_summary>
	<brief_title>A Study of the Rules for Insulin Dosing in Patients Using Multiple Daily Injections</brief_title>
	<detailed_description>Subjects with stable type 1 diabetes mellitus on multiple daily insulin injections including basal and bolus will be selected in order to determine the correct insulin dosing formulas. Subjects will be placed on continuous glucose sensor (CGMS) and an isocaloric diet. Subjects will have the CGMS downloaded daily and the insulin doses adjusted if necessary. Subject will do four SMBGs daily to calibrate CGMS and on last day a 7-point SMBG. subjects will be on lispro and glargine insulin. Basal insulin will be once a day.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Age: &gt;17 years Type 1 diabetes Diabetes duration &gt; 3 months On treatment with multiple daily injections either one or more basal insulin injections each day for 6 weeks HbA1c &lt;9.0% Stable HbA1c in the proceeding 3 months (i.e., change &lt;1%) Demonstrated adherence to visits and instructions Attend a class in meal carbohydrate content estimation or have demonstrated knowledge of carbohydrate counting Major stress event during or for 6 weeks before the evaluation Taking a medication that can alter insulin sensitivity Within one week of menses Unstable eating or activity pattern Pregnancy Weight gain of &gt; 1.5 kg during the preceding 3 months Serum creatinine of &gt;1.5 mg/dl Active liver disease Evidence of autonomic neuropathy, especially gastroparesis Any antidiabetic medication other than insulin Treatment with continuous subcutaneous insulin infusion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>diabetes mellitus type 1</keyword>
	<keyword>continuous glucose monitoring</keyword>
</DOC>